References
- Beiske AG, Pedersen ED, Czujko B, Myhr KM. Pain and sensory complaints in multiple sclerosis. Eur J Neurol 2004; 11: 479–482
- Clauss R, Sathekge M, Nel W. Transient improvement of spinocerebellar ataxia with zolpidem. New Engl J Med 2004; 351: 511–512
- Cohen L, Chaaban B, Habert MO. Transient improvement of aphasia with zolpidem. New Engl J Med 2004; 350: 949–950
- Crestani F, Low K, Keist R, Mandelli M, Mohler H, Rudolph U. Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol 2001; 59: 442–445
- Cubala WJ, Landowski J. Seizure following sudden zolpidem withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 539–540
- Deutsche Gesellschaft für Neurologie. 2009. Insomnie. Stuttgart: Georg Thieme. 654ff
- Dundar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess 2004; 8: iii–125
- Farver DK, Khan MH. Zolpidem for antipsychotic-induced parkinsonism. Ann Pharmacother 2001; 35: 435–437
- Finger S. A happy state of mind: a history of mild elation, denial of disability, optimism, and laughing in multiple sclerosis. Arch Neurol 1998; 55: 241–250
- Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003; 98: 1371–1378
- Hoffmann F, Pfannkuche M, Glaeske G. [High usage of zolpidem and zopiclone. Cross-sectional study using claims data]. Nervenarzt 2008; 79: 67–72
- Hoffmann F, Scharffetter W, Glaeske G. [Use of zolpidem and zopiclone on private prescriptions between 1993 and 2007]. Nervenarzt 2009; 80: 578–583
- Huang MC, Lin HY, Chen CH. Dependence on zolpidem. Psychiatry Clin Neurosci 2007; 61: 207–208
- Liappas IA, Malitas PN, Dimopoulos NP, Gitsa OE, Liappas AI, Nikolaou C, et al. Zolpidem dependence case series: possible neurobiological mechanisms and clinical management. J Psychopharmacol. 2003; 17: 131–135
- NICE – National Institute for Clinical Excellence. 2004. Guidance on the use of zaleplone, zolpidem and zopiclone for the short term management of insomnia. Technology Appraisal Guidance ed. London, NICE
- Perrault G, Morel E, Sanger DJ, Zivkovic B. Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther 1992; 263: 298–303
- Ruzicka E, Roth J, Jech R, Busek P. Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease. Mov Disord 2000; 15: 734–735
- Shadan FF, Poceta JS, Kline LE. Zolpidem for postanoxic spasticity. South Med J 2004; 97: 791–792
- Wang WT, Chen YY, Wu SL, Wei TS, Liu SY. Zolpidem dramatically improved motor and speech function in a patient with central pontine myelinolysis. Eur J Neurol 2007; 14: e9–10